Alpha Cognition Inc. Cost of Revenue
Alpha Cognition Inc. (ACOG) reported Cost of Revenue of $391.06 thousand for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Expense Statement › Cost of Sales
us-gaap:CostOfRevenue · last filed 2026-08-13
- Alpha Cognition Inc. cost of revenue for the quarter ending 2026-06-30 was $391.06K, a 91.83% increase year-over-year.
- Alpha Cognition Inc. cost of revenue for the quarter ending 2025-06-30 was $203.86K.
- Alpha Cognition Inc. cost of revenue for the quarter ending 2025-03-31 was $12.69K.
| Period end | Cost of Revenue 3 month | Cost of Revenue 6 month | Cost of Revenue 6 month as first filed |
|---|---|---|---|
| 2026-06-30 | $391.06K 10-Q · filed 2026-08-13 | $668.22K 10-Q · filed 2026-08-13 | |
| 2025-06-30 | $203.86K 10-Q · filed 2026-08-13 | $1.05M 10-Q · filed 2026-08-13 | $67.92K 10-Q · filed 2025-08-14 |
| 2025-03-31 | $12.69K 10-Q · filed 2025-05-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Coherus Oncology, Inc. (CHRS) | United States | $0.182B | -1.63 |
| PRECISION BIOSCIENCES INC (DTIL) | United States | $0.175B | -3.95 |
| Voyager Therapeutics, Inc. (VYGR) | United States | $0.173B | -1.99 |
| Protara Therapeutics, Inc. (TARA) | United States | $0.198B | -3.22 |
| Compass Therapeutics, Inc. (CMPX) | United States | $0.204B | -5.35 |
| Acumen Pharmaceuticals, Inc. (ABOS) | United States | $0.162B | -1.83 |
| Outlook Therapeutics, Inc. (OTLK) | United States | $0.162B | -4.90 |
| Alector, Inc. (ALEC) | United States | $0.213B | -1.90 |
| Humacyte, Inc. (HUMA) | United States | $0.155B | -2.26 |
| ANAVEX LIFE SCIENCES CORP. (AVXL) | United States | $0.218B | -18.37 |